
Biopharmaceuticals (i.e., biological medicines sourced from genetically-engineered living systems) for treatment of human diseases have become a significant percentage of the pharmaceutical industry. And not just the recombinant DNA-derived proteins and monoclonal antibodies (both from the innovators and biosimilars); but now, an increasing awareness of the importance of
Title | : | The Challenge of CMC Regulatory Compliance for Biopharmaceuticals |
Author | : | John Geigert |
Language | : | en |
Rating | : | |
Type | : | PDF, ePub, Kindle |
Uploaded | : | Apr 03, 2021 |
Post Your Comments: